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T-regulatory cells suppress anti-tumour immunity in cancer patients and in murine tumour models. Furthermore, their activity is likely
to have an effect on the effectiveness of immunotherapeutic treatments for cancer. Here we describe the current status of
developing clinical strategies for modulating Treg activity in cancer patients.
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A strong relationship exists between T-regulatory cells (Tregs) and
the development and progression of cancer. Tregs within the
tumour, ascites and peripheral blood of patients with cancer are
associated with poor prognosis. Increasingly, evidence suggests
that Tregs protect tumours from the potentially effective immune
responses. Thus, new anti-cancer strategies involving interference
in Treg biology or depletion of Tregs are of critical importance.
Among the plethora of agents known to affect Tregs, there are
some conventional therapeutic agents. Here we describe the
current status of clinical modalities, both specifically designed to
target Tregs and those drugs for which their immunomodulatory
function may constitute a hitherto undefined mode of action.
A BRIEF HISTORY OF Tregs
Suppressor cells, first observed in the 1970s, were thought to be
antigen-specific and, once activated, targeted CD4þ T-helper
cells, blocking activation and progression of both humoral and
cell-mediated immunity. Subsequently, the mechanism of suppres-
sion was found to be more complicated and, because of the lack of
any phenotypic marker, the term T-‘suppressor’ cells drifted out of
use. More than 20 years later, CD4þ T cells expressing interleukin
(IL)-2 receptor a-chain (CD25) that maintained tolerance against
auto-immune diseases in mouse models were identified (Sakaguchi
et al, 1995). These ‘Tregs’ make up 5–10% of naı ¨ve CD4þ T cells
in the periphery, and seem to be a heterogeneous group of CD4þ
cells variable in their mechanism of action.
The Treg subtypes that are affected by the treatments discussed
in this review are unclear in many cases. In the following section a
brief overview of Tregs is intended to introduce key cell types that
may play a role in tumour biology. A complete review of Treg
biology is beyond the scope of this paper, and has been extensively
reviewed elsewhere.
The thymus-derived Tregs or natural Tregs (nTregs) are easily
identified by CD4 and high CD25 expression. However, differ-
entiating between CD4þ T cells and human Tregs cells is difficult,
as over a quarter of human T cells express CD25 to some degree.
Recently, FOXP3 (Forkhead box P3 transcription factor) has
helped to differentiate the suppressor population of CD4þ
CD25þ cells. Initially identified as a mutated gene in the scurfy
mouse strain, which developed autoimmunity because of CD4þ
T-cell hyperactivity and increased production of pro-inflammatory
cytokines, FOXP3 was found to be a key regulatory gene for Tregs.
The exact mechanism of nTreg suppression is not clearly defined,
but is thought to be involved in cell-to-cell contact through
membrane-bound TGF-b (seen in certain in vitro studies),
cytokine release (IL-10, TGF-b, IL-35), signalling through cAMP
and possibly extracellular adenosine. It has been difficult to
identify an all-encompassing suppressive pathway as yet in in vivo
studies and in human studies in particular.
Inducible Tregs are very similar in function to nTregs but derive
from FOXP3 negative naı ¨ve T cells in the periphery under specific
stimulation. Once induced these cell begin to express FOXP3,
cytotoxic T-lymphocyte antigen-4 (CTLA-4), and secrete IL-10 and
TGF-b.
Tr1 cells are adaptive Tregs that differ from nTregs in their
ability to produce the IL-10 and TGF-b in large amounts, which
both suppress naı ¨ve and memory CD4þ T-cell function in murine
in vitro studies (Groux et al, 1997). Tr1 cells are also induced by
antigen-mediated TCR activation in the presence of IL-10
(Roncarolo et al, 2006).
Th3 cells (another adaptive Treg subset vital for the main-
tenance of oral tolerance) achieve their suppressive effects through
the secretion of IL-10, IL-4 and large amounts of TGF-b, and
indirectly by promoting the differentiation of antigen-specific
FOXP3 Tregs peripherally. Th3 cells differ from Tr1 in their
dependence on TGF-b for differentiation from CD4þCD25–T
cells (Carrier et al, 2007).
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yet, not all have been identified and some may well be the same cell
at different stages of activation. In fact, when treating patients it is
difficult to discern the type of Treg that is being targeted, as the
main mode of Treg evaluation is the peripheral blood sampling
(in which FOXP3 seems to be the main identifier) and basic
functional analysis. Inducible Tregs and natural Tregs seem to be
the important cell types in immune regulation in cancer patients.
One particular murine in vivo study suggests that conversion of
naı ¨ve CD4þ T cells into antigen-specific iTregs takes place within
the tumour microenvironment, and is driven by the tumour itself
(Zhou and Levitsky, 2007). At present the specific contributions of
the different subtypes within the tumour milieu is not certain.
Tregs AND MALIGNANCY
T-regulatory cells are implicated in the development of auto-
immunity, allergy and rejection of organ transplants, as well as the
suppression of immune responses to cancer. There is an increased
presence of CD4þCD25þ T cells in a wide spectrum of human
malignancies, such as lung, head and neck, ovarian, gastrointest-
inal and skin. These cells are found in relatively high concentra-
tions in blood, ascites, tumour draining lymph nodes and within
the tumour milieu of cancer patients. Increased accumulation of
Tregs conferred a poor prognosis for patients with ovarian cancer
(Curiel et al, 2004). However, several recent studies showed
conflicting prognostic data for some haematological, specifically
B-cell lymphoma, malignancies in which higher numbers of
FOXP3þ cells (taken to be Tregs) were shown to correlate with
improved survival. Curiously, in B-CLL it has been shown that
high Treg numbers also correlate with advanced disease stage. The
differences in prognostic benefit of Tregs between haematological
malignancy and carcinoma remain to be clarified. However, it has
been suggested that the earlier shown suppressive effects of Tregs
on B-cell function may explain the benefit of high Treg numbers in
B-cell lymphoma patients (Tzankov et al, 2008). It is worth adding
that many of these studies concentrate only on the numbers or
percentages of FOXP3þ cells and, although this clearly identifies
Tregs, it is our experience that many tumour cells also express
FOXP3, lending the possibility that not all cells identified as FOXP3
positive are, in fact, Tregs.
Much research has been undertaken to determine how Tregs
help tumours escape detection and elimination. Tregs affect many
of the immune cells that reside in the tumour milieu and draining
lymph nodes, including the effector T cells, natural killer cells and
dendritic cells. These cells are paramount for effective cancer
immunity and thus would explain the role of Tregs, which
accumulate in large numbers.
IMPACT OF CHEMOTHERAPY
Modulating the action of Tregs represents one aspect in the
prevention of tumour ‘immune’ escape, which potentially
enhances immunosurveillance and the effects of other immuno-
therapeutic modalities. A number of agents affect Tregs in a
clinical context, some of which are designed specifically to target
known receptors on Tregs, whereas others, including conventional
chemotherapeutic drugs, have modulatory effects on Tregs
although their exact mode of action is often unknown.
Some commonly used chemotherapeutic agents, such as
methotrexate and cyclophosphamide, can have immunostimula-
tory and anti-angiogenic effects at lower doses without the toxic
effects associated with higher doses. This new concept of treatment
is on the basis of the more frequent or ‘metronomic’ administra-
tion of a dose substantially lower than the maximum tolerated
dose. Cyclophosphamide depletes CD4þCD25þ Tregs in mice
injected with tolerogenic syngeneic tumour cells (Ghiringhelli et al,
2004). Depletion leads to a decrease in tumour cell growth and
eventual rejection of established tumours when used in combi-
nation with an immunotherapeutic agent (PROb tumour cells
mixed with BCG). Cyclophosphamide not only depletes Treg
numbers by increasing their susceptibility to apoptosis, but
also has a deleterious effect on their function in a murine in vitro
study. There is some evidence that the negative effect of low-dose
cyclophosphamide is attributable to a decreased expression of
glucocorticoid-induced tumour necrosis factor receptor (GITR)
and FOXP3. The restoration of Treg numbers and the function
10 days after cyclophosphamide administration indicates the
reversibility of its effects (Lutsiak et al, 2005).
Low-dose cyclophosphamide has been used in a metronomic
regimen in patients with end-stage cancer (Ghiringhelli et al, 2007)
and conventional hormone-resistant prostate cancer (Lord et al,
2007), potentiating its anti-angiogenic and immunostimulatory
properties and avoiding its high-dose toxic effects. Though the
phase II prostate cancer study showed no relationship between
clinical response and circulating Treg numbers, there was a
reduction in TGF-b expression, which is crucial for nTreg-
mediated suppression. The study of nine patients with metastatic
end-stage cancer treated with metronomic low-dose cyclophos-
phamide (50mg orally, once daily for a week with the ensuing
week off) did, however, show a selective reduction in T-regulatory
cell numbers with a preservation of total number of lymphocytes
and natural killer cells. Contrary to the evidence provided thus far,
one recent French study evaluating varying doses of cyclophos-
phamide showed neither improved clinical benefit, nor concomi-
tant decrease in peripheral Treg numbers, nor any decline in
FOXP3 expression (Audia et al, 2007). However, in contrast to the
continuous low-dose regimen, they administered a single bolus
dose. Moreover, histological analysis of tumours from five patients
suggested a reduction in CD25þ T-cell aggregation in the tumour
vicinity and increased infiltration of CD8þ T cells, which hints
at an immunostimulatory benefit.
A number of other chemotherapeutics used in standard
practice modulating Tregs, include gemcitabine, mitoxanthrone,
fludarabine and COX-2 inhibitors. Although Treg modulation is by
no means the primary mode of action for these drugs, it is
interesting to speculate that these, and potentially other standard
chemotherapeutics, have secondary functions mediated through
their effects on Tregs.
Gemcitabine, a nucleoside analogue, used in pancreatic cancer
inhibits DNA synthesis in the S-phase of the cell cycle.
Gemcitabine has a mixed effect on the peripheral blood
lymphocytes. When administered to patients with non-small cell
lung cancer in a phase I study, lymphopenia with particular
decrease in effector T-cell populations was observed (Levitt et al,
2004). The pancreatic cancer patients receiving gemcitabine had an
initial reduction in absolute lymphocyte number, which eventually
stabilise (Plate et al, 2005). There was no observable reduction in
CD25þ T-cell number, but an increase in naı ¨ve T-cell activation
was observed. In a phase I study of colon cancer patients, there was
a rise in CTLs with a concomitant decrease in CD25þCD4þT
cells in clinical responders (Correale et al, 2005). Despite the
favourable objective clinical response across the three studies, the
effect of gemcitabine on lymphocyte populations is mixed. In
a phase I study in lung cancer, there was a profound effect on
the rapidly dividing cells including lymphocytes. It is interesting
that Gemcitabine was able to eliminate myeloid-suppressor
cells (MSCs), which also have immunosuppressive properties, in
a murine study leading to increased activation of CD8þ T cells
(Suzuki et al, 2005). Gemcitabine has broader effects on a variety
of suppressive cells, and the clinical effect seen in some studies
evaluating Tregs may be partially related to the elimination of
MSCs. Further work is needed to define its mechanism of action.
Mitoxantrone is an anthracenedione that binds to deoxyribose
on DNA causing strand break up and unravelling. When
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response is seen in approximately one-third of the participants.
Though there was no change in the CD4/CD8 ratio, there was
a significant drop in B lymphocytes, T-‘suppressor’ cells and
CD25þ cells (Barni et al, 1991). Despite this depletion there
was no observable relationship with the tumour response. Thus
mitoxantrone, although ineffective in breast cancer as a single
modality, may be a suitable agent for combined use with immuno-
therapy, which may have clinical benefit in breast cancer.
Fludarabine, which has good efficacy in the treatment of chronic
lymphocytic leukaemia, has the capability to inhibit Treg expansion
and maintains CTL function in co-culture studies (Hegde et al,
2008). Though patients treated with fludarabine have a general
reduction in CD4þ T cells, in a study where patients with CLL were
treated with fludarabine a preferential decline in CD4þCD25þ
Tregs was noted due to apoptosis (Beyer et al,2 0 0 5 ) .A no p t i m u m
dose must be determined that will safeguard effector T-cell function
if fludarabine is to be used in an immunomodulatory role.
COX-2 expression is closely allied to many aspects of tumour
progression. Patients taking aspirin and other nonsteroidal anti-
inflammatory drugs have significant protection from developing
colorectal cancer. In vitro tumour-derived prostaglandin E2 (PGE2)
increases FOXP3 expression and Treg inhibitory activity. COX-2
inhibition significantly reduces tumour Treg infiltration in murine
studies. There are increased concentrations of PGE2 in the
peripheral blood of patients with colorectal cancer, and in vitro
analysis showed that Indomethacin (a COX-2 inhibitor) reverses
Treg-mediated anti-tumour suppression (Yaqub et al, 2007). In a
recent clinical study, patients with colon cancer were randomised
to either an oral NSAID (indomethacin or celebrex) or a control
drug (esomeprazole) for 3 days preoperatively. Histological
analysis of resected specimens showed a significant increase in
CD8þ tumour-infiltrating T-cells and decreased expression of
FOXP3 and IL-10 in patients who took indomethacin (Lonnroth
et al, 2008). In preclinical models COX-2 inhibitors, for example
celecoxib, enhance the effects of dendritic cell vaccines. Although
celecoxib clearly has effects when delivered as a single modality, it
is interesting to speculate that some of the effects of COX-2
inhibition may be because of the suppressive effects on Tregs.
DIRECT TARGETING OF Tregs
A number of recently developed reagents target Tregs directly,
either through recognition of CD25 or through CTLA-4 blockade.
Both approaches lack specificity, as they target essential immuno-
regulatory molecules on T-effector cells. However, this reflects the
difficulty of differentiating between Tregs and other effector cells.
CD4þCD25þ Treg depletion by administration of anti-CD25
antibodies in mice produced a significant increase in anti-tumour
activity, along with an increased incidence of autoimmune
diseases. Multimodal immunotherapy using monoclonal anti-
bodies and vaccines has also been studied in murine models, in
which the Treg inhibition leads to an improved effector cell
response to the vaccine. More recently, there has been an increased
use of recombinant toxic proteins designed to target T cells with
high CD25 expression (but spares T lymphocytes not involved in
immune suppression).
LMB-2 is a fusion protein consisting of a single-chain Fv
fragment of a CD25-specific monoclonal antibody attached to a
38kDa fragment of Pseudomonas exotoxin A. In a preclinical
in vitro study in which human PBMCs were incubated with LMB-2,
CD4þCD25þTregs were selectively depleted (Attia et al, 2006). A
phase I study LMB-2 in CD25þ T-cell malignancies showed one
complete and seven partial responses among a group of 20 patients
receiving more than 60mgkg
–1 per cycle with acceptable minor
toxic effects (Kreitman et al, 2000). Administration of LMB-2
followed by peptide vaccination in patients with melanoma showed
a steep drop in FOXP3þCD4þCD25þ Tregs. Despite a lack of
objective clinical response, these preliminary data are encouraging
and provides a method for Treg elimination (Powell Jr et al,
2007b).
Denileukin diftitox (DAB389IL-2, Ontak, Seragen Incorporated,
Hopkinton, MA, USA) is a fusion protein combining human IL-2
and an enzymatically active domain of diphtheria toxin. It binds
preferentially to cells expressing the high-affinity IL-2 receptor
(CD25, CD122 and CD132) and is internalised ultimately leading to
cell death. Diftitox is efficacious in certain types of T-cell
lymphoma with high CD25 expression (Talpur et al, 2006) (see
Table 1). Diftitox administration in advanced renal cell carcinoma
(RCC) patients before dendritic cell vaccination resulted in a
reduction in the peripheral Tregs and Treg-mediated immuno-
suppression. This effect on solid tumours was further corroborated
in melanoma patients for whom enhanced antigen-specific CD8 T-
cell activity was seen (Mahnke et al, 2007). However, a study
evaluating the treatment of melanoma patients with diftitox not
only failed to show any favourable clinical improvement, but also
showed no change in number or suppressive properties of
peripheral Tregs (Attia et al, 2005a). This remains a controversial
area and awaits further data to resolve the discrepancy.
Table 1 Phase I studies administering diftitox
Study Diftitox dosing strategy
Number of
patients CR PR SD PD Toxicity
Earlier treated indolent
non-Hodgkin’s lymphoma
(Kuzel et al, 2007)
Diftitox administered at 18mgkg
 1
per day for 5 days every 21 days
29 (3 unevaluable) 0 3 14 9 Mainly grade I and II but
also one fatal
thrombolembolism
Combined with rituximab for
relapsed/refractory B-cell
non-Hodgkin’s lymphoma
(Dang et al, 2007)
Rituximab at a 375mgm
–2on day
1 of each 3-week cycle i.v. diftitox
18mgkg
–1per day on days 2–6
of cycle
38 6 6 7 19 Mainly grade I and II toxicity
but loss of visual acuity in
two patients
Relapsed/refractory T-cell
non-Hodgkin’s lymphoma
(Dang et al, 2007)
Diftitox 18mgkg
–1 per day for
5 days every 3 weeks for up to
eight cycles
27 6 7 7 7 Mainly grade I toxicity
Earlier treated chronic lymphocytic
leukemia (Frankel et al)
Diftitox 5 days every 21 days at
18mgkg
–1per day for up to
8 cycles
22 tolerating
42 cycles
1 5 6 9 Moderate toxicities
Metastatic melanoma and renal-cell
carcinoma (Attia et al)
Diftitox administered for 5 days
every 21 days in seven patients
at 9mgkg
–1 per day, and in six
patients at 18mgkg
–1per day
12 metastatic
melanoma, one
metastatic renal-cell
carcinoma
00 N o t
mentioned
Not
mentioned
11 patients developed
transient grade III/IV toxicity
T-regulatory cell modulation
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the treatment of certain cancers, such as RCC and melanoma,
where it is associated with increased effector T-cell responses
(Rosenberg et al, 1994). Tregs are induced by the administration of
therapeutic amounts of IL-2. Thus administration of IL-2 to
ovarian cancer patients resulted in an increased FOXP3þ Treg
proliferation, which was inversely proportional to the number of
Tregs present before treatment. However, there was a drop in
Tregs in responders to IL-2 once treatment was discontinued
(Wei et al, 2007). A similar increase in Treg number and function
occurred when patients with RCC and melanoma were treated with
IL-2 (Ahmadzadeh and Rosenberg, 2006). The tumour regression
seen on administration of IL-2 may be associated with concomi-
tant activation of tumour-specific T cells. Clearly the relationship
between effector function and Treg numbers requires greater
understanding.
Depletion of Tregs may provide a beneficial state in effective
immunotherapy. However, depletion of CD25þ Tregs in meta-
static melanoma (MM) patients treated with IL-2 resulted in the
rapid reaccumulation of suppressive CD25þFOXP3þ Tregs in
the periphery (Powell Jr et al, 2007a). No objective tumour
regression was seen in these patients. Depletion of Tregs by diftitox
in RCC patients resulted in a refractory repopulation of 75% of
the original number within 2 months in another study (Dannull
et al, 2005). This rapid reversal indicates the need for serial
treatment doses with its ensuing side effects to maintain low
Treg numbers. Future strategies should consider this possible
refractory accumulation of Tregs, which could attenuate clinical
responses.
Cytotoxic T-lymphocyte antigen-4 is found in high levels on
CD4þCD25þ Tregs where it suppresses activation and prolifera-
tion by binding to CD80/CD86 receptors on effector T cells. The
importance of CTLA-4 activation in T-cell homoeostasis was
shown in a murine study in which CTLA-4-deficient mice died
after massive lymphoproliferation leading to multi-organ failure.
Thus, CTLA-4 blockade provides a mode of Treg modulation. The
effect of anti-CTLA-4 antibodies on solid tumours was initially
recognised in mice in the late 1990s. Other animal studies showed
the potency of anti-CTLA-4 antibodies against poorly immuno-
genic tumours when used with other modes of treatment. Anti-
CTLA-4 administered alone can be effective against transplanted
and spontaneous tumour models in mice. Antibody therapy has
reached early human clinical trials. At present, two humanised
anti-CTLA-4-blocking antibodies, MDX-010 (Ipilimumab) and
CP-675206 (Tremelimumab), have been used in phase I and II
trials.
In a phase I trial treating MM, 36% of patients showing grade
III/IV autoimmune toxicity had tumour regression compared with
5% in patients without autoimmune symptoms (Attia et al, 2005b).
A further trial combining varied doses of MDX-010 with high-dose
IL-2 showed synergy compared with earlier studies evaluating IL-2
alone in MM (Maker et al, 2005b). Further analysis of the
peripheral blood mononuclear cells in patients undergoing anti-
CTLA-4 treatment for stage IV MM and RCC has highlighted (by
means of in vitro co-culture proliferation assay and FOXP3
expression) that there is no inhibition of the suppressive activity of
CD4þCD25þ T cells, but a probable enhancement of effector
cell function (Maker et al, 2005a) (see Table 2).
Tremelimumab is less extensively studied. In vitro studies show
enhanced T-cell activation. A phase I trial undertaken to establish
dosing for phase II concluded that a single dose up to 15mgkg
–1is
sufficient to break peripheral tolerance. Out of 39 patients with
advanced malignancy two patients had a complete response and
two had a partial response. Tremelimumab was shown not only
able to suppress Treg activity, but also to replenish the effector and
memory CD4þ and CD8þ T-cell numbers, contributing to its
anti-tumour effect (Menard et al, 2008). Thus, it has been argued
that depletion of Tregs may be secondary in importance to
modulating the ratio of CD8
þ effector cells to Tregs, which may be
effected through the influence of anti-CTLA-4 antibodies on
effector cell numbers. Further phase III studies to evaluate the
response to Tremelimumab on patients with MM are planned, and
studies on colorectal and lung cancer patients are currently being
completed (Cranmer and Hersh, 2007). One phase III randomised
study comparing tremelimumab as a first-line treatment with
chemotherapy in patients with MM failed to show any improve-
ment in survival and was abandoned after three treatment-related
deaths.
These antibodies may well enhance the effectiveness of cancer
vaccines when used in combination with other modalities. Sadly,
studies to determine the effect of combining GVAX whole-cell
vaccine technology for prostate cancer with tremelimumab are
likely to be shelved after the failure of phase III studies of GVAX vs
docetaxel. Further clinical studies will be required in the future if
Table 2 Phase I and II studies administering anti-CTLA-4 treatment
Study Disease
Number
of patients Dosing of anti-CTLA-4 Side effects Objective response
Phase I (Phan et al,
2008)
Metastatic
melanoma
14 3mgkg
–1 (three times weekly)+gp100
melanoma-associated antigen
Six grade III/IV
autoimmune toxicity
Three in total
Phase I study
(Hodi et al, 2003)
Metastatic
melanoma
7
Five grade I/II and I had
IV grade autoimmune
toxicity
Two tumour necrosis and
two T-cell infiltration
Ovarian 2 3mgkg
–1 (one dose) One tumour necrosis and
two reduction/stabilization of
Ca-125
Phase I study
(Sanderson
et al, 2005)
Metastatic
melanoma
19 0.3mgkg
–1+peptide immunizations (n¼7) 0 Seven in total
1.0mgkg
–1+peptide immunizations (n¼7) One grade III
autoimmune toxicity
3.0mgkg
–1+peptide immunizations
(n¼5)
Three III autoimmune
toxicity
Phase I study
(Attia et al, 2005b)
Metastatic
melanoma
56 3mgkg
–1 ( three times weekly)+peptide
vaccinations (n¼29)
14 grade III/IV
autoimmune toxicity
4
3mgkg
–1 then 1mgkg
–1 (three times weekly)+
peptide vaccinations (n¼27)
3
Phase I and II study
(Maker et al, 2005a)
Metastatic
melanoma
36 0.1mgkg
–1 + IL-2 (n¼3) Five grade III/IV
autoimmune toxicity
0
0.3mgkg
–1 + IL-2 (n¼3)
3
1.0mgkg
–1 + IL-2 (n¼3)
2.0mgkg
–1 + IL-2 (n¼3)
3.0mgkg
–1 + IL-2 (n¼24) 5
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combination with vaccines.
Despite these setbacks there is still much excitement in the
recent literature regarding the potential of CTLA-4-blocking
antibodies. However, it is important to bear in mind that there
is ‘heterogeneity’ in the kinetics of clinical response, with
beneficial responses taking place a long time after the adminis-
tration and unexplained patterns of disease progression (Saenger
and Wolchok, 2008). Blockage of CTLA-4 is not complication free
with the development of a spectrum of immune-related adverse
effects. These side effects will be more frequent with increasing
administration of anti-CTLA-4 treatment.
FUTURE STRATEGIES FOR Treg MODULATION
Targeting glucocorticoid-induced tumour-necrosis factor (TNF)-
related peptide receptor is another avenue for modulation of
Tregs. GITR is constitutively expressed by Tregs, and when
stimulated by either agonist antibodies (DTA-1) to GITR or
GITR ligand (Kim et al, 2003) leads to suppression of Treg
cell activity in murine studies. It is also expressed, albeit at
lower levels, on CD4þ and CD8þ T-effector cells and when
stimulated results in enhanced proliferation and possible resis-
tance to Treg-mediated suppression. DTA-1 when injected into
mice bearing B16 melanoma (a weakly immunogenic tumour)
resulted in concomitant immunity and rejection of secondary
tumour implantation along with protection against the primary
tumour (Turk et al, 2004). This shows the importance of Treg
attenuation in the presence of a weakly immunogenic tumour and
the development of concomitant immunity against melanoma
implantation.
In a different model, injection of DTA-1 8 days after the
inoculation of BALB/c mice with a methylcholanthrene-induced
fribrosarcoma produced tumour-specific immunity (Ko et al,
2005). The tumours were infiltrated by large numbers of CD4þ
and CD8þ effector cells, and an increase in INF-g was noted.
DTA-1 also has a synergistic effect when co-administered with
anti-CTLA-4 antibodies, whereas the effect is less impressive when
administered with anti-CD25 monoclonal antibodies. However, as
with anti-CTLA-4 antibodies, autoimmune symptoms have been
detected. At the time of writing human studies have yet to
commence.
Imatinib (Glivec, Novartis UK, Frimley, Surrey, UK), a tyrosine
kinase inhibitor, is the treatment of choice for advanced
gastrointestinal stromal tumours. More recently in patients with
chronic myeloid leukaemia treated with stem cell transplantation,
imatinib was given to accentuate the graft-vs-leukaemia reaction.
This resulted in a significant dose-dependent decrease in CD69
GITR, CTLA-4 and FOXP3 expression, and IL-10 and TGF-b
secretion by Tregs (Chen et al, 2007). Though imatinib may not be
the most suitable treatment for graft-vs-leukaemia reactions, it
may be of benefit in Treg downregulation as an adjunct to cancer
immunotherapy. Other tyrosine kinase inhibitors such a suntinib
(effective in the treatment of RCC) also attenuate Treg numbers in
mice (Hipp et al, 2007).
Bevicuzimab is an effective antibody at preventing tumour
angiogenesis and works by preventing the activation of tyrosine
kinase. In RCC patients treated with Bevacizumab a drop in Treg
numbers was observed in clinical responders (Passalacqua et al,
2008). The actual mechanism that leads to Treg attenuation and
depletion is yet to be determined.
A recent in vitro study showed the ability of lenalidomide
(Revlimid, Celgene Corporation, Summit, NJ, USA; CC-5013) and
CC-4047 to suppress Treg function and proliferation; effects that
may be mediated by downregulation of FOXP3 (Galustian et al,
2008). Both drugs are active against multiple myeloma, and it is
tempting to speculate that this is mediated by their anti-Treg
properties, although co-stimulatory and anti-angiogenic activity
have also been shown.
Fluorescence-activated cell sorting isolated human Tregs also
seem to be sensitive to CD95-induced apoptosis, whereas isolated
effector T cells seem to be resistant. This may be a method of
ensuring that Tregs are eliminated in the acute phase of an
immune response (Fritzsching et al, 2005).
Activation of toll-like receptor (TLR) pathways in dendritic cells
confers resistance of naı ¨ve T cells to Treg-mediated suppression.
TLR ligands also have a direct effect on Tregs, countering their
suppressive properties without the need for dendritic cells. TLR 8
(present in high levels on Tregs) activation by its ligand RNA 40 (a
specific oligoribonucleotide ) negated the suppressive function of
Tregs in mice (Peng et al, 2005). Though TLR8 activation is
mediated by the MyD88 intracellular pathway, its downstream
effects, which ultimately lead to Treg suppression, require
elucidation and potential effects on immunotherapy have yet to
be determined.
Activation of OX40, a co-stimulatory molecule belonging to the
TNF receptor superfamily, leads to expansion of CD4þ and
CD8þ T cells resulting in tumour rejection in murine models
(Weinberg et al, 2000). A recent murine study showed that OX40
activation not only reversed effector T-cell hyporesponsiveness,
but also negated Treg function leading to tumour rejection
(Piconese et al, 2008).
CONCLUSION
The realisation that Tregs play a major role in the development of
human cancer has led to the discovery that these cells are effective
in shielding cancers from a potential immune response. Moreover,
the dramatic effects of some conventional chemotherapeutic
agents may not solely be because of a direct anti-cancer effect,
but may also rely on an indirect and additive effect on the cellular
immune response to cancer.
Here we focused on the potential clinical effects of immune
modulation of Tregs in humans, as successful murine studies do
not always translate to success in humans; possibly reflecting
differences in Treg types and function between the two species. At
present direct therapeutic effect on human Tregs are generally
gauged by observing cell number and crude function, mainly in the
peripheral blood. It has been argued that peripheral blood
sampling does not reflect the most relevant compartment, and
that monitoring the intratumoural environment through biopsy or
fine-needle aspirates may provide more useful information about
the effector functions of Tregs in cancer. Few studies delve into the
tumour milieu to objectively assess effects on intratumoural Tregs.
The study by Powell investigating the effect of LMB-2 on three
patients with MM suggests that there is a concomitant depletion of
Tregs peripherally and within the tumour. The numbers within
this study are very small as serial tumour sampling from patients is
not easy. Careful phase I and II studies will be required in future to
ascertain any therapeutic or prognostic effect with more focus on
real-time changes occurring within the tumour milieu.
With the availability of several new monoclonal antibodies and a
reassessment of other treatments whose mechanisms are poorly
understood, new protocols will be able to target Treg cells in order
to make anti-cancer treatments more effective. At present, the best
of method of Treg modulation is yet to be discerned and many
questions are still unanswered as to which type of cells are most
effective against tumours; however, the future of Treg modulation
within the remit of cancer immunotherapy looks promising.
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